Management

Biography PhotoWilliam G. Rice, Ph.D.
Chairman, President & Chief Executive Officer
Through a rich blend of leadership roles in industry, government and academic sectors, Dr. Rice has accrued more than 20 years of know-how and forged a diverse set of executive, operational, business development, financial, and product research and development skills. Prior to Aptose, Dr. Rice served as the President, Chief Executive Officer and Chairman of the Board of Cylene Pharmaceuticals, Inc. In that role he led the company’s strategic, financing, and business development activities, resulting in the development and sale of small molecule therapeutic programs designed to exploit CK2-mediated pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Before Cylene, Dr. Rice was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine. Over the course of his career, Dr. Rice has identified multiple new molecular drug targets, delivered multiple first-in-class drugs to the clinic, and published peer-reviewed findings in Science, Nature, Cancer Cell, Nature Medicine, Proceedings of the National Academy of Sciences, among other prestigious journals. Dr. Rice holds a Ph.D. in Biochemistry from Emory University and was a postdoctoral trainee in the Department of Internal Medicine at the University of Michigan Medical Center.... read more

Biography PhotoDaniel D.  Von Hoff, M.D., F.A.C.P.
Senior Vice President, Medical Affairs
Dr. Daniel D. Von Hoff is currently Physician-in-Chief and Distinguished Professor of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He is also a Professor of Medicine, Mayo Clinic and serves as a Phoenix Children’s Hospital clinician. In 1989, Dr. Von Hoff was a founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and ten years later he became Director of the Cancer Center and Professor of Medicine at the University of Arizona. In addition, Dr. Von Hoff was a founder of Ilex Oncology which obtained FDA approval for two new anticancer agents – alemtuzumab and clofarabine. Ilex was sold to Genzyme Corporation for $1 billion in 2004. Dr. Von Hoff also served a six-year term on President Bush’s National Cancer Advisory Board. He is a past president of the American Association for Cancer Research (AACR), was on the AACR and the American Society of Clinical Oncology (ASCO)'s Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and founder and Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Dr. Von Hoff became a Professor in the Departments of Medicine and Cellular and Structural Biology at the University of Texas Health Science Center, San Antonio. He was Associate Editor for two AACR journals, Clinical Cancer Research and Cancer Research. Dr. Daniel D. Von Hoff is currently Physician-in-Chief and Distinguished Professor of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He is also a Professor of Medicine, Mayo Clinic and serves as a Phoenix Children’s Hospital clinician. In 1989, Dr. Von Hoff was a founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and ten years later he became Director of the Cancer Center and Professor of Medicine at the University of Arizona. In addition, Dr. Von Hoff was a founder of Ilex Oncology which obtained FDA approval for two new anticancer agents – alemtuzumab and clofarabine. Ilex was sold to Genzyme Corporation for $1 billion in 2004. Dr. Von Hoff also served a six-year term on President Bush’s National Cancer Advisory Board. He is a past president of the American Association for Cancer Research (AACR), was on the AACR and the American Society of Clinical Oncology (ASCO)'s Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and founder and Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Dr. Von Hoff became a Professor in the Departments of Medicine and Cellular and Structural Biology at the University of Texas Health Science Center, San Antonio. He was Associate Editor for two AACR journals, Clinical Cancer Research and Cancer Research. ... read more

Biography PhotoStephen B. Howell, M.D.
Acting Chief Medical Officer
Dr. Howell is a Distinguished Professor of Medicine at the University of California, San Diego, and Associate Director for Clinical Research at the Moores UCSD Cancer Center and head of the Pharmacology and Toxicology Laboratory at the Center for Cancer Nanotechnology Excellence at UCSD. His work focuses on the development of novel drugs and drug delivery systems for the treatment of cancer, and on the molecular and genetic mechanisms underlying the development of drug resistance. He is the author of more than 300 papers. Dr. Howell conducted much of the early pharmacokinetic information and clinical trials work on intraperitoneal chemotherapy for the treatment of ovarian cancer. His laboratory has contributed importantly to the current understanding of how platinum-containing drugs enter, traffic through, and exit from ovarian cancer cells, and how such cells become resistant to these drugs. Dr. Howell is a graduate of Harvard Medical School and was trained as a medical oncologist and pharmacologist at the Massachusetts General Hospital, the National Institutes of Health and the Dana Farber Cancer Institute.... read more

Biography PhotoAvanish Vellanki
Senior Vice President, Chief Business Officer
Avanish Vellanki brings a breadth of industry experience, having served in senior-level corporate development and strategic planning roles and as a healthcare banker and biotechnology equity research analyst at leading global investment banks. In his role as Chief Business Officer, he is responsible for global business development, licensing, and corporate strategy. Prior to joining Aptose Biosciences in late 2013, Mr. Vellanki was the Senior Vice President of Investment Banking at Wedbush Securities, where he focused on the biotechnology sector. Before he joined Wedbush Securities, Mr. Vellanki held the position of Senior Director of Corporate Development at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), a biotechnology company focused on the development of oncology therapeutics, most notably Kyprolis® (carfilzomib) for patients with hematologic malignancies and other cancers. Previously, Mr. Vellanki served as Vice President in Citigroup’s Global Healthcare Investment Banking, where he focused on large cap global biopharma strategic and financial advisory. Mr. Vellanki began his career at Bear Stearns as an equity research analyst covering the small/mid-cap biotechnology sector. He is also a co-founder and Chairman of the Board of Independence Brewing Company Pvt. Ltd., one of the first craft microbreweries in India. Mr. Vellanki holds a BA from Carleton College, an MBS in Biochemistry from the University of Minnesota and an MBA from the Carlson School of Management at the University of Minnesota.... read more

Biography PhotoGregory Chow
Senior Vice President, Chief Financial Officer
Greg Chow brings more than 18 years of corporate finance, capital markets, and financial accounting experience to Aptose. In his role as Chief Financial Officer, Mr. Chow has global responsibility for all corporate finance and accounting functions. Prior to Aptose Biosciences, Mr. Chow served as Managing Director, Director of Private Placements at Wedbush Securities, where he led private placement capital activities within the Life Sciences Investment Banking Group. Before joining Wedbush, he was a Director in the Private Placements/Equity Capital Markets Group at RBC Capital Markets, where he headed the private placement team and managed capital activities in the Healthcare Group. Mr. Chow’s transactional experience covers a broad range of equity and equity-linked financings that include Initial Public Offerings, Follow-Ons, Confidentially Marketed Public Offerings, Registered Directs, Private Investment in Public Equities (PIPEs) and private placements for private companies. Prior, he led the Private Capital Group at Wells Fargo Securities and was a Senior Auditor at BDO Seidman, LLP in the Century City, CA office. Mr. Chow is a Certified Public Accountant (inactive) in the State of California. Mr. Chow received his MBA in Finance from The Wharton School at the University of Pennsylvania, and his BA in Business Economics, with an emphasis in Accounting, from the University of California, Santa Barbara.... read more

Biography PhotoElizabeth Williams
Vice President, Finance and Administration
Ms. Williams has been with Aptose since 2004, previously in the role of Director of Finance. While at Aptose, she has been responsible for a broad range of activities with a focus on financial reporting and regulatory compliance. Ms. Williams has been involved in more than $75 million in financings including public offerings, private placements, rights offerings, corporate reorganizations and debt (issuance and redemption). Prior to joining Aptose, Ms. Williams was an Audit Manager at Ernst and Young LLP with a focus on publicly listed multinational companies. Ms. Williams is a Chartered Professional Accountant and Chartered Accountant and received a Bachelor of Business Administration from Wilfrid Laurier University.... read more

Biography PhotoErnest Kitt
Vice President, Development and Technical Operations
Ernest Kitt, B.S., M.S., has held a series of senior leadership positions in the pharmaceutical industry for over 17 years and has played a pivotal role in successfully leading companies through the complexities of drug development. His roles led him to sit on senior governance boards, as well as position him to make key decisions for a drug's development in the clinic, to lead commercial launches across the globe, to develop regulatory strategy, to analyze fiscal impact and to guide the future strategic direction for the development of many compounds. Immediately prior to joining Aptose, Ernest held the position at Onyx Pharmaceuticals (an Amgen company) of Molecule Lead for Kyprolis® (carfilzomib) in Clinical Operations for the continued development of Kyprolis® (carfilzomib) for patients with hematologic malignancies and other cancers. Ernest has been a leader in drug development of products primarily in oncology, but has also led the development of products for infectious disease, neurology, dermatology, transplant, and pulmonary indications in both large and small pharmaceutical and biotechnology companies, including roles most notably at Amgen, Bavarian Nordic, Medicinova, and Vical.... read more